The use of pigs for human transplants stems from a historical partnership between the Mayo Clinic and Hormel Foods to breed smaller 'minipigs' for lab research. This agricultural project, combined with pigs' anatomical similarities and lower disease-transmission risk compared to primates, established them as the primary source for replacement organs.

eGenesis prioritizes organs like kidneys and hearts because they show good outcomes in non-human primates and have high physiological similarity to humans. Livers are more challenging due to differences in synthetic function, dictating a different clinical approach (perfusion) instead of direct transplant.

In treating conditions like heart failure, Gordian's approach is not to replace damaged cells but to use gene therapy to "reprogram" existing, dysfunctional ones. This strategy aims to restore the normal function of the patient's own tissue rather than engaging in the more complex task of rebuilding it.

Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

Unlike direct-to-patient cell therapies, xenotransplantation's process of creating a pig serves as a biological filter. If gene edits have significant off-target effects, a healthy animal cannot be produced. This 'viable animal' checkpoint validates the genetic engineering before clinical use.

The "replacement strategy" for longevity analogizes the body to a complex machine like an iPhone. It's often impossible to fix a shattered screen (a failing organ), but swapping the part is simple and effective. This reframes the approach to thousands of "incurable" diseases from repair to replacement.

A major unknown was the surgical procedure itself. After four cases, surgeons report that transplanting a pig kidney is remarkably similar to a human-to-human allogeneic transplant. This de-risks the surgical component significantly, with patients often leaving the ICU in one night.

Instead of using large commercial pigs and then editing genes to limit organ growth, eGenesis selected the Yucatan mini-pig breed from the start. This breed's organs naturally grow to a size compatible with human recipients, simplifying the genetic engineering required.

The field was stalled by the risk of transmitting porcine retroviruses to humans. The problem was intractable because 50-70 viral copies are spread across the pig genome. CRISPR's unique ability to efficiently make that many edits was the specific breakthrough needed to mitigate this key safety risk.